• C de Roquetaillade, B G Chousterman, D Tomasoni, M Zeitouni, E Houdart, A Guedon, P Reiner, R Bordier, E Gayat, G Montalescot, M Metra, and A Mebazaa.
• Department of Anesthesiology and Critical Care, Hôpital Lariboisière (AP-HP), Paris, France; Inserm U942 MASCOT, Paris, France. Electronic address: charles.de-roquetaillade@aphp.fr.
• Int. J. Cardiol. 2021 Jan 15; 323: 281-284.

IntroductionCOVID-19 infection is commonly complicated with pro-thrombotic state and endothelial dysfunction. While several studies reported a high incidence of venous thromboembolic events. The occurrence of arterial thromboses are yet rarely described and could be underestimated.ObjectivesTo describe the clinical and biological characteristics of COVID-19 patients presenting with an associated arterial thromboembolic event.Material And MethodsWe performed a retrospective multicentric study in 3 centers between France and Italy. All patients with a confirmed SARS-CoV-2 infection and arterial thromboembolic events were included in the analysis.ResultsFrom March 8th to April 25th 2020, we identified 20 patients (24 events) with arterial thromboembolic events over 209 admitted patients (9.6%) with severe COVID-19 infection. Arterial thrombotic events included acute coronary occlusions (n = 9), stroke (n = 6), limb ischemia (n = 3), splenic infarcts (n = 3), aortic thrombosis (n = 2) and occlusive mesenteric ischemia (n = 1). At the time of the event, 10/20 (50%) of patients received thromboprohylaxis, 2/20 (10%) were receiving treatment dose anticoagulation and 5/20 (25%) were receiving antiplatelet therapy.ConclusionOur observations suggest that serious arterial thrombotic events might occur in Covid-19 patients. However, the exact incidence of such events and the best way to prevent them yet remains to be investigated.Copyright © 2020 Elsevier B.V. All rights reserved.

34 keywords...

hide…